Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Barclays Virtual Gene Editing & Therapy Summit Transcript

May 24, 2023 / 02:05PM GMT
Release Date Price: $1.43 (-8.93%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang, and I'm SMID cap biotech analyst at Barclays. Welcome to our 7th Gene Editing & Gene Therapy Summit. I would like to thank all the participants, investors, companies and especially our event team and corporate access team, who made this event possible. And with that, I would like to introduce our next presenter, Mark McClung, Chief Operating Officer from Sangamo. Mark, well, thank you very much for joining us today.

D. Mark McClung
Sangamo Therapeutics, Inc. - Executive VP & COO

Good morning, Gena. It's a pleasure.

Questions & Answers

Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Okay. So maybe I will start with your Fabry program, ST-920. So maybe regarding your regulatory path, I know you just received the Fast Track destination, also expect discussion with the FDA to finalize the Phase III trial design in the summer. And so maybe a few questions there. Have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot